<DOC>
	<DOCNO>NCT00254202</DOCNO>
	<brief_summary>The purpose study determine safety efficacy iloperidone compare placebo active comparator treatment patient schizophrenia acute exacerbation .</brief_summary>
	<brief_title>Efficacy Safety Iloperidone Compared With Placebo Active Control Subjects With Acute Schizophrenia</brief_title>
	<detailed_description>Schizophrenia severe mental illness affect estimate 1 % world 's population . Patients schizophrenia suffer productive symptom ( e.g. , hallucination delusion ) , deficit symptom ( e.g. , reduction absence normal behavior emotion ) . Other symptom include reduced ability recall learn new information . Iloperidone development treatment symptom schizophrenia . This trial test safety efficacy iloperidone patient acute exacerbation disease .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Subject schizophrenia . Subject must sign write consent form . Clinically significant disease heart , kidney , liver gastrointestinal system Psychiatric disorder schizophrenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Atypical antipsychotic</keyword>
	<keyword>psychosis</keyword>
</DOC>